Business
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
- Dr. Ruffner is a US-trained hematologist/oncologist with over 25 years of clinical care, oncology biotechnology and pharmaceutical drug development
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"- Dr. Ruffner is a US-trained hematologist/oncologist with over 25 years of clinical care, oncology biotechnology and pharmaceutical drug development experience\n - Mr. Levine has over 20 years of corporate and investment banking experience in the biotechnology and pharmaceutical sectors\n - Inducement Grants Issued Pursuant to Nasdaq Listing Rule 5635(c)(4)\n\n\nSAN DIEGO, July 12, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Katherine L. Ruffner, M.D., as chief medical officer (CMO) and James E. Levine as chief financial officer (CFO). \n\n \n \n \n \n \n \n\n \nDr. Ruffner has over 25 years of clinical care, oncology biotechnology, and pharmaceutical drug development experience. Mr. Levine has extensive corporate and investment banking experience in the biotechnology industry, including corporate finance, capital markets and business development. In their newly created roles at Cardiff Oncology, Dr. Ruffner will be responsible for overseeing the strategy and execution of clinical programs, as well as the identification and evaluation of pipeline expansion opportunities. In his role as CFO, Mr. Levine will guide Cardiff Oncology's financial strategy and lead its business development efforts, which will focus on maintaining an optimal financial benefit-risk balance across each of the Company's programs. Mr. Levine will also serve as the Company's principal financial and accounting officer.\n\"With these appointments we have continued to execute on our goal of strengthening our executive team through the addition of highly talented individuals with complementary skill sets,\" said Mark Erlander, Ph.D., chief executive officer of Cardiff Oncology. \"They come at a time of significant company opportunity and growth, as our lead program in KRAS-mutated metastatic colorectal cancer is poised for important clinical milestones and we have a meaningful and exciting platform of new clinical indications on the horizon. Katherine's extensive experience in oncology clinical care and drug development, including advancing novel cancer treatments towards reg...